Pilot Study of the Pre-Conditioning Effects of Anti-Macrophage Therapy Using PD 0360324 in Recurrent Platinum-Resistant Epithelial Ovarian Cancer
Latest Information Update: 05 Nov 2021
At a glance
- Drugs PD 360324 (Primary) ; Cyclophosphamide
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Adverse reactions; Pharmacodynamics
- 08 Mar 2019 Planned End Date changed from 31 Dec 2020 to 6 Feb 2019.
- 08 Mar 2019 Planned primary completion date changed from 31 Dec 2020 to 6 Feb 2019.
- 08 Mar 2019 Status changed from not yet recruiting to withdrawn prior to enrolment.